BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hetrombopag readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Hetrombopag\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07408648-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270415
DTEND;VALUE=DATE:20270416
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07408648)
DESCRIPTION:Hetrombopag\, phase 2\, Chemotherapy-Induced Thrombocytopenia.\
 nStudy: A Clinical Study on the Efficacy and Safety of Hetrombopag in the 
 Treatment of Thrombocytopenia Induced by Gynecological Tumor Therapy\nEsti
 mated primary completion: 15 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/hetrombopag#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07408648
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07101627-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07101627)
DESCRIPTION:Hetrombopag\, phase 2.\nStudy: A Prospective\, Multicenter Clin
 ical Study of Hetrombopag in the Prevention of Thrombocytopenia Caused by 
 Lung Cancer Therapy\nEstimated primary completion: 30 April 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/hetrombopag#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07101627
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818916-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Hetrombopag: Phase na readout est. (NCT06818916)
DESCRIPTION:Hetrombopag\, phase na.\nStudy: Hetrombopag in Promoting Platel
 et Engraftment After Auto-HSCT in Children With Neuroblastoma\nEstimated p
 rimary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/hetrombopag#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06818916
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07788456-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Hetrombopag: Phase 4 readout est. (NCT07788456)
DESCRIPTION:Hetrombopag\, phase 4.\nStudy: Multi-target Drugs Sequential Co
 mbination Therapy in Adults Patients With Newly Diagnosed Primary Immune T
 hrombocytopenia\nEstimated primary completion: 30 May 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/hetrombopag#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07788456
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06478537-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT06478537)
DESCRIPTION:Hetrombopag\, phase 2.\nStudy: TPO-RA Treatment on Immune Toler
 ance Induction of ITP Patients With Sustained Platelet Recovery After Trea
 tment Termination\nEstimated primary completion: 20 June 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/hetrombopag#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06478537
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925398-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Hetrombopag: Phase 3 readout est. (NCT07925398)
DESCRIPTION:Hetrombopag\, phase 3.\nStudy: Hetrombopag for Thrombocytopenia
  in Patients Scheduled for Elective Hepatic Interventional Diagnostic and 
 Therapeutic Procedures: A Clinical Study\nEstimated primary completion: 15
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hetr
 ombopag#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07925398
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334093-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271115
DTEND;VALUE=DATE:20271116
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07334093)
DESCRIPTION:Hetrombopag\, phase 2.\nStudy: A Study of Hetrombopag Combined 
 With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CT
 IT) in Solid Tumor Patients.\nEstimated primary completion: 15 November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/hetrombopag#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07334093
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07243418-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07243418)
DESCRIPTION:Hetrombopag\, phase 2\, Chemotherapy-Induced Thrombocytopenia.\
 nStudy: Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in 
 Breast Cancer: An Exploratory\, Dual-Cohort\, Phase 2 Study\nEstimated pri
 mary completion: 30 November 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/hetrombopag#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07243418
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933146-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07933146)
DESCRIPTION:Hetrombopag\, phase 2.\nStudy: Sequential Hetrombopag and Recom
 binant Human Thrombopoietin for Cancer Therapy-Induced Thrombocytopenia\nE
 stimated primary completion: 30 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/hetrombopag#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07933146
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07647029-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07647029)
DESCRIPTION:Hetrombopag\, phase 2\, Chemotherapy-Induced Thrombocytopenia.\
 nStudy: A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secon
 dary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae\nEstimate
 d primary completion: 29 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/hetrombopag#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07647029
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252375-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07252375)
DESCRIPTION:Hetrombopag\, phase 2\, Chemotherapy-Induced Thrombocytopenia.\
 nStudy: A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia
  Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal 
 Carcinoma\nEstimated primary completion: 30 May 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/hetrombopag#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07252375
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286032-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Hetrombopag: Phase 3 readout est. (NCT07286032)
DESCRIPTION:Hetrombopag\, phase 3\, Chemotherapy-Induced Thrombocytopenia.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine
  Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia
  (ExCIT)\nEstimated primary completion: December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hetrombopag#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07286032
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010237-11067@assetmemo.bio
DTSTAMP:20261121T004015Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Hetrombopag: Phase 2 readout est. (NCT07010237)
DESCRIPTION:Hetrombopag\, phase 2.\nStudy: Dose-attenuated IST and Hetrombo
 pag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia\nEstimat
 ed primary completion: 31 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/hetrombopag#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07010237
URL:https://assetmemo.bio/drug/hetrombopag#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
